Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients

Expert Review of Anti-Infective Therapy

Volumn 15, Issue 2, 2017, Pages 93-110

  Abad, C L ^a,b   Razonable, R R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

Author keywords

Herpesvirus; infection; solid organ transplant

Indexed keywords

ACICLOVIR; AMENAMEVIR; ANTIVIRUS AGENT; BENZIMIDAVIR; BRINCIDOFOVIR; CIDOFOVIR; CYCLOPROPAVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; LETERMOVIR; PRITELIVIR; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; VALNIVUDINE; VALOMACICLOVIR; NEW DRUG;

ACUTE KIDNEY FAILURE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL RESISTANCE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CONFUSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENITAL HERPES; GRAFT RECIPIENT; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HERPES LABIALIS; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES SIMPLEX VIRUS 4; HERPES SIMPLEX VIRUS 5; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INTRAOCULAR HYPOTENSION; JAUNDICE; KIDNEY FAILURE; KIDNEY PANCREAS TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; META ANALYSIS (TOPIC); MONONUCLEOSIS; MULTICENTER STUDY (TOPIC); NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPEN STUDY; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENT DISEASE; REVIEW; SEIZURE; SEROPREVALENCE; SOMNOLENCE; TREATMENT OUTCOME; UVEITIS; VACCINATION; VARICELLA ZOSTER VIRUS; VIRAL CLEARANCE; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SHEDDING; VOMITING; CHEMICAL STRUCTURE; CHEMISTRY; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTIONS; HERPES SIMPLEX; ORGAN TRANSPLANTATION; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS INFECTIONS; DRUGS, INVESTIGATIONAL; HERPES SIMPLEX; HERPES ZOSTER; HUMANS; MOLECULAR STRUCTURE; ORGAN TRANSPLANTATION;

EID: 85009450677     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2017.1266253     Document Type: Review

References (202)

1. Zuckerman RA, Limaye AP., Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am J Transplant. 2013;13 Suppl 3:55–66; quiz 66.
2. Shiley K, Blumberg E. Herpes viruses in transplant recipients:HSV, VZV, human herpes viruses, and EBV. Hematol Oncol Clin North Am. 2011;25(1):171–191.
3. Miller GG, Dummer JS. Herpes simplex and varicella zoster viruses:forgotten but not gone. Am J Transplant. 2007;7(4):741–747.
4. Schillinger JA, Xu F, Sternberg MR, et al. National seroprevalence and trends in herpes simplex virus type 1 in the United States, 1976-1994. Sex Transm Dis. 2004;31(12):753–760.
5. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997;337(16):1105–1111.
6. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964–973.
7. Wilck MB, Zuckerman RA. Herpes simplex virus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:121–127.
8. Naraqi S, Jackson GG, Jonasson O, et al. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis. 1977;136(4):531–540.
9. Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients:transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis. 1988;158(1):124–131.
10. Smyth RL, Higenbottam TW, Scott JP, et al. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation. 1990;49(4):735–739.
11. Pettersson E, Hovi T, Ahonen J, et al. Prophylactic oral acyclovir after renal transplantation. Transplantation. 1985;39(3):279–281.
12. Seale L, Jones CJ, Kathpalia S, et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA. 1985;254(24):3435–3438.
13. Razonable RR. Management of viral infections in solid organ transplant recipients. Expert Rev Anti Infect Ther. 2011;9(6):685–700.
14. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues:mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55(2):459–472.
15. Langston AA, Redei I, Caliendo AM, et al. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood. 2002;99(3):1085–1088.
16. Nichols WG, Boeckh M, Carter RA, et al. Transferred herpes simplex virus immunity after stem-cell transplantation:clinical implications. J Infect Dis. 2003;187(5):801–808.
17. Schulte EC, Sauerbrei A, Hoffmann D, et al. Acyclovir resistance in herpes simplex encephalitis. Ann Neurol. 2010;67(6):830–833.
18. Malvy D, Treilhaud M, Bouee S, et al. A retrospective, case-control study of acyclovir resistance in herpes simplex virus. Clin Infect Dis. 2005;41(3):320–326.
19. Fishman JA. Overview:cytomegalovirus and the herpesviruses in transplantation. Am J Transplant. 2013;13 Suppl 3:1–8; quiz 8.
20. Alcaide ML, Abbo L, Pano JR, et al. Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab. Clin Transplant. 2008;22(4):502–507.
21. Arness T, Pedersen R, Dierkhising R, et al. Varicella zoster virus-associated disease in adult kidney transplant recipients:incidence and risk-factor analysis. Transpl Infect Dis. 2008;10(4):260–268.
22. Manuel O, Kumar D, Singer LG, et al. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant. 2008;27(1):11–16.
23. Herrero JI, Quiroga J, Sangro B, et al. Herpes zoster after liver transplantation:incidence, risk factors, and complications. Liver Transpl. 2004;10(9):1140–1143.
24. Levitsky J, Kalil A, Meza JL, et al. Herpes zoster infection after liver transplantation:a case-control study. Liver Transpl. 2005;11(3):320–325.
25. Gourishankar S, McDermid JC, Jhangri GS, et al. Herpes zoster infection following solid organ transplantation:incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4(1):108–115.
26. Griffiths P, Whitley R, Snydman DR, et al. Contemporary management of cytomegalovirus infection in transplant recipients:guidelines from an IHMF workshop, 2007. Herpes. 2008;15(1):4–12.
27. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm. 2005;62(8 Suppl 1):S7–13.
28. Razonable RR, Emery VC. Management of CMV infection and disease in transplant patients. 27-29 February 2004. Herpes. 2004;11(3):77–86.
29. Betts RF, Hanshaw JB. Cytomegalovirus (CMV) in the compromised host(s). Annu Rev Med. 1977;28:103–110.
30. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001;184(11):1461–1464.
31. Isada CM, Yen-Lieberman B, Lurain NS, et al. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transpl Infect Dis. 2002;4(4):189–194.
32. Kruger RM, Shannon WD, Arens MQ, et al. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation. 1999;68(9):1272–1279.
33. Lautenschlager I, Razonable RR. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation:review. Transpl Int. 2012;25(5):493–502.
34. Razonable RR. Human herpesviruses 6, 7 and 8 in solid organ transplant recipients. Am J Transplant. 2013;13 Suppl 3:67–77; quiz 77–68.
35. Delbridge MS, Karim MS, Shrestha BM, et al. Colitis in a renal transplant patient with human herpesvirus-6 infection. Transpl Infect Dis. 2006;8(4):226–228.
36. Nash PJ, Avery RK, Tang WH, et al. Encephalitis owing to human herpesvirus-6 after cardiac transplant. Am J Transplant. 2004;4(7):1200–1203.
37. Singh N, Carrigan DR, Gayowski T, et al. Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient. Transplantation. 1995;60(11):1355–1357.
38. Vinnard C, Barton T, Jerud E, et al. A report of human herpesvirus 6-associated encephalitis in a solid organ transplant recipient and a review of previously published cases. Liver Transpl. 2009;15(10):1242–1246.
39. Lee SO, Brown RA, Eid AJ, et al. Chromosomally integrated human herpesvirus-6 in kidney transplant recipients. Nephrol Dial Transplant. 2011;26(7):2391–2393.
40. Lee SO, Brown RA, Razonable RR. Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients. Transplantation. 2011;92(2):224–229.
41. Lee SO, Brown RA, Razonable RR. Chromosomally integrated human herpesvirus-6 in transplant recipients. Transpl Infect Dis. 2012;14(4):346–354.
42. Pellett PE, Ablashi DV, Ambros PF, et al. Chromosomally integrated human herpesvirus 6:questions and answers. Rev Med Virol. 2012;22(3):144–155.
43. Anton A, Cervera C, Pumarola T, et al. Human herpesvirus 7 primary infection in kidney transplant recipients. Transplantation. 2008;85(2):298–302.
44. Razonable RR, Zerr DM. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S97–100.
45. Razonable RR, Paya CV. The impact of human herpesvirus-6 and −7 infection on the outcome of liver transplantation. Liver Transpl. 2002;8(8):651–658.
46. Baldwin K. Ganciclovir-resistant human herpesvirus-6 encephalitis in a liver transplant patient:a case report. J Neurovirol. 2011;17(2):193–195.
47. Bounaadja L, Piret J, Goyette N, et al. Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir. J Clin Virol. 2013;58(1):279–282.
48. Ljungman P. Prophylaxis against herpesvirus infections in transplant recipients. Drugs. 2001;61(2):187–196.
49. Ashley RL, Corey L. Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus. J Clin Invest. 1984;73(3):681–688.
50. Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet. 1982;2(8298):571–573.
51. Serota FT, Starr SE, Bryan CK, et al. Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation. JAMA. 1982;247(15):2132–2135.
52. Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47(1):153–205.
53. Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc. 2011;86(10):1009–1026.
54. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23(4):689–712.
55. Elion GB. Mechanism of action and selectivity of acyclovir. Am J Med. 1982;73(1a):7–13.
56. Jiang J, Zhu Y, Jian G, et al. Randomized case-controlled trial of oral low-dose acyclovir for prevention of virus infections in recipients of renal allografts. Chin Med J (Engl). 1995;108(6):459–461.
57. Jirasiritham S, Sumethkul V, Chiewsilp P, et al. Prevention of recurrent herpes infection after renal transplantation by low-dose oral acyclovir. Transplant Proc. 1994;26(4):2125–2126.
58. Schlech WF, 3rd, Meagher N, Cohen AD, et al. A randomized double-blind placebo controlled trial of oral acyclovir in renal allograft recipients. Can J Infect Dis. 1993;4(2):84–88.
59. Stoffel M, Squifflet JP, Pirson Y, et al. Effectiveness of oral acyclovir prophylaxis in renal transplant recipients. Transplant Proc. 1987;19(1 Pt 3):2190–2193.
60. Tang IY, Maddux MS, Veremis SA, et al. Low-dose oral acyclovir for prevention of herpes simplex virus infection during OKT3 therapy. Transplant Proc. 1989;21(1 Pt 2):1758–1760.
61. Arazi HC, Delgado D, Carosella V, et al. Prevention of symptomatic infection by herpesvirus in patients after heart transplantation. Transplant Proc. 1999;31(6):2530.
62. Carrier M, Pelletier GB, Cartier R, et al. Prevention of herpes simplex virus infection by oral acyclovir after cardiac transplantation. Can J Surg. 1992;35(5):513–516.
63. Barkholt L, Lewensohn-Fuchs I, Ericzon BG, et al. High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients. Transpl Infect Dis. 1999;1(2):89–97.
64. De Clercq E. Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother. 1993;32 Suppl A:121–132.
65. Bean B, Aeppli D. Adverse effects of high-dose intravenous acyclovir in ambulatory patients with acute herpes zoster. J Infect Dis. 1985;151(2):362–365.
66. Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459–465.
67. Ernst ME, Franey RJ. Acyclovir- and ganciclovir-induced neurotoxicity. Ann Pharmacother. 1998;32(1):111–113.
68. Hellden A, Lycke J, Vander T, et al. The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. J Antimicrob Chemother. 2006;57(5):945–949.
69. Bacon TH, Levin MJ, Leary JJ, et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev. 2003;16(1):114–128.
70. Gateley A, Gander RM, Johnson PC, et al. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis. 1990;161(4):711–715.
71. Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis. 2004;39 Suppl 5:S248–257.
72. Ljungman P, Ellis MN, Hackman RC, et al. Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis. 1990;162(1):244–248.
73. Weller S, Blum MR, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54(6):595–605.
74. Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother. 1997;31(2):185–191.
75. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340(19):1462–1470.
76. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370(9605):2127–2137.
77. Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Arch Intern Med. 1996;156(15):1729–1735.
78. Pergam SA, Limaye AP. Varicella zoster virus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:138–146.
79. Pavlopoulou ID, Syriopoulou VP, Chelioti H, et al. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin Microbiol Infect. 2005;11(9):736–743.
80. Reischig T, Jindra P, Mares J, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation. 2005;79(3):317–324.
81. Reischig T, Opatrny K, Jr., Bouda M, et al. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transpl Int. 2002;15(12):615–622.
82. Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8(1):69–77.
83. Kacer M, Kielberger L, Bouda M, et al. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus:an economic perspective. Transpl Infect Dis. 2015;17(3):334–341.
84. Egan JJ, Carroll KB, Yonan N, et al. Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation:a randomized trial. J Heart Lung Transplant. 2002;21(4):460–466.
85. Kimberlin DW, Whitley RJ. Antiviral therapy of HSV-1 and −2. In:Arvin A, Campadelli-Fiume G, Mocarski E, editors. Human herpesviruses:biology, therapy, and immunoprophylaxis. Cambridge:Cambridge University Press; 2007.
86. Gill KS, Wood MJ. The clinical pharmacokinetics of famciclovir. Clin Pharmacokinet. 1996;31(1):1–8.
87. Faro S. A review of famciclovir in the management of genital herpes. Infect Dis Obstet Gynecol. 1998;6(1):38–43.
88. Chacko M, Weinberg JM. Famciclovir for cutaneous herpesvirus infections:an update and review of new single-day dosing indications. Cutis. 2007;80(1):77–81.
89. Tyring S, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest. 2001;19(1):13–22.
90. Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994;38(10):2454–2457.
91. Fletcher C, Sawchuk R, Chinnock B, et al. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther. 1986;40(3):281–286.
92. Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol. 2000;16(1):25–40.
93. Griffiths PD, Boeckh M. Antiviral therapy for human cytomegalovirus. In:Arvin A, Campadelli-Fiume G, Mocarski E, editors. Human herpesviruses:biology, therapy, and immunoprophylaxis. Cambridge:Cambridge University Press; 2007.
94. Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs. 1994;48(3):455–484.
95. Frank KB, Chiou JF, Cheng YC. Interaction of herpes simplex virus-induced DNA polymerase with 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem. 1984;259(3):1566–1569.
96. Mar EC, Cheng YC, Huang ES. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1983;24(4):518–521.
97. Tocci MJ, Livelli TJ, Perry HC, et al. Effects of the nucleoside analog 2ʹ-nor-2ʹ-deoxyguanosine on human cytomegalovirus replication. Antimicrob Agents Chemother. 1984;25(2):247–252.
98. Winston DJ, Wirin D, Shaked A, et al. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet. 1995;346(8967):69–74.
99. Singh N, Yu VL, Mieles L, et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med. 1994;120(5):375–381.
100. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients:a randomized, placebo-controlled trial. J Infect Dis. 2002;185(7):854–860.
101. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44(10):2811–2815.
102. Singh N, Paterson DL, Gayowski T, et al. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients:a randomized, controlled trial. Transplantation. 2000;70(5):717–722.
103. Gane E, Saliba F, Valdecasas GJ, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet. 1997;350(9093):1729–1733.
104. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S78–86.
105. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96(4):333–360.
106. Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9(5):1205–1213.
107. Li F, Kenyon KW, Kirby KA, et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis. 2007;45(4):439–447.
108. Limaye AP. Antiviral resistance in cytomegalovirus:an emerging problem in organ transplant recipients. Semin Respir Infect. 2002;17(4):265–273.
109. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35(7):866–872.
110. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356(9230):645–649.
111. Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185(1):20–27.
112. Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis:therapeutic implications and outcomes. Clin Transplant. 2008;22(2):162–170.
113. Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther. 2004;2(1):27–41.
114. Brown F, Banken L, Saywell K, et al. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37(2):167–176.
115. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet. 2005;44(5):495–507.
116. Caldes A, Colom H, Armendariz Y, et al. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus. Antimicrob Agents Chemother. 2009;53(11):4816–4824.
117. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4(4):611–620.
118. Kalil AC, Freifeld AG, Lyden ER, et al. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients:an evidence-based reassessment of safety and efficacy. Plos One. 2009;4(5):e5512.
119. Kalil AC, Mindru C, Botha JF, et al. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis:a systematic review and meta-analysis. Liver Transpl. 2012;18(12):1440–1447.•• Provides a summary of studies on prophylaxis among high risk CMV SOT recipients.
120. Levitsky J, Singh N, Wagener MM, et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant. 2008;8(1):158–161.
121. Humar A, Limaye AP, Blumberg EA, et al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease:two-year results of the IMPACT study. Transplantation. 2010;90(12):1427–1431.
122. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation:a randomized, controlled trial. Ann Intern Med. 2010;152(12):761–769.
123. Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation:a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant. 2011;30(9):990–996.• Provides data on safety of prolonged CMV prophylaxis among high risk lung transplant recipients.
124. Boivin G, Goyette N, Farhan M, et al. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol. 2012;53(3):208–213.
125. Halim MA, Al-Otaibi T, Gheith O, et al. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients. Exp Clin Transplant. 2016;5:526–534.•• Gives insightful information on use of low dose Valganciclovir among kidney transplant recipients.
126. Gabardi S, Asipenko N, Fleming J, et al. Evaluation of low- versus high-dose valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients. Transplantation. 2015;99(7):1499–1505.
127. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation:direct and indirect treatment comparison meta-analysis. Clin Infect Dis. 2011;52(3):313–321.• Summarizes information regarding use of low versus high dose valganciclovir for CMV among SOT recipients.
128. Julian KG, Shattahi E, Burg JE, et al. Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients. Transplant Proc. 2013;45(9):3414–3417.
129. Stevens DR, Sawinski D, Blumberg E, et al. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl Infect Dis. 2015;17(2):163–173.
130. Young PG, Rubin J, Angarone M, et al. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients:a single-center retrospective cohort study. Transpl Infect Dis. 2016;18(3):390–395.
131. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7(9):2106–2113.
132. Len O, Gavalda J, Aguado JM, et al. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis. 2008;46(1):20–27.
133. Kim JM, Kwon CH, Joh JW, et al. Oral valganciclovir as a preemptive treatment for cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients. Plos One. 2015;10(5):e0123554.
134. Mengelle C, Rostaing L, Weclawiak H, et al. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients. J Med Virol. 2015;87(5):836–844.
135. Togashi J, Sugawara Y, Hashimoto M, et al. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation:a randomized trial. Biosci Trends. 2011;5(5):217–222.
136. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13 Suppl 4:93–106.
137. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48(2):199–226.
138. Balfour HH, Jr., Fletcher CV, Erice A, et al. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrob Agents Chemother. 1996;40(12):2721–2726.
139. Jabs DA, Enger C, Forman M, et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. 1998;42(9):2240–2244.
140. Balfour HH, Jr., Benson C, Braun J, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr. 1994;7(3):254–260.
141. Beaufils H, Deray G, Katlama C, et al. Foscarnet and crystals in glomerular capillary lumens. Lancet. 1990;336(8717):755.
142. Jacobson MA, Causey D, Polsky B, et al. A dose-ranging study of daily maintenance intravenous foscarnet therapy for cytomegalovirus retinitis in AIDS. J Infect Dis. 1993;168(2):444–448.
143. Lor E, Liu YQ. Neurologic sequelae associated with foscarnet therapy. Ann Pharmacother. 1994;28(9):1035–1037.
144. Lea AP, Bryson HM. Cidofovir. Drugs. 1996;52(2):225–230; discussion 231.
145. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36(2):127–143.
146. Wolf DL, Rodriguez CA, Mucci M, et al. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. J Clin Pharmacol. 2003;43(1):43–51.
147. Cherrington JM, Fuller MD, Lamy PD, et al. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy:relationship to clinical outcome. J Infect Dis. 1998;178(6):1821–1825.
148. Kazory A, Singapuri S, Wadhwa A, et al. Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir. J Antimicrob Chemother. 2007;60(1):193–194.
149. Ambati J, Wynne KB, Angerame MC, et al. Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol. 1999;83(10):1153–1158.
150. Tseng AL, Mortimer CB, Salit IE. Iritis associated with intravenous cidofovir. Ann Pharmacother. 1999;33(2):167–171.
151. Lu H, Thomas S. Maribavir (ViroPharma). Curr Opin Investig Drugs. 2004;5(8):898–906.
152. Maribavir:1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263. Drugs R D. 2007;8(3):188–192. PMID:17472414.
153. Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46(8):2365–2372.
154. Krosky PM, Baek MC, Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol. 2003;77(2):905–914.
155. Williams SL, Hartline CB, Kushner NL, et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother. 2003;47(7):2186–2192.
156. Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 2002;46(8):2373–2380.
157. Lalezari JP, Aberg JA, Wang LH, et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother. 2002;46(9):2969–2976.
158. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients:a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403–5410.
159. Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients:a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12(11):3021–3030.•• One of the first studies on use of Maribavir among SOT recipients.
160. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants:a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–292.
161. Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12(6):489–496.
162. Trofe J, Pote L, Wade E, et al. Maribavir:a novel antiviral agent with activity against cytomegalovirus. Ann Pharmacother. 2008;42(10):1447–1457.
163. Painter W, Robertson A, Trost LC, et al. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother. 2012;56(5):2726–2734.
164. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity:current state of the art. Antiviral Res. 2009;82(2):A84–98.
165. Aldern KA, Ciesla SL, Winegarden KL, et al. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol. 2003;63(3):678–681.
166. Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother. 2002;46(4):991–995.
167. Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res. 2003;59(3):163–171.
168. Painter GR, Hostetler KY. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 2004;22(8):423–427.
169. Quenelle DC, Lampert B, Collins DJ, et al. Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis. 2010;202(10):1492–1499.
170. Rinaldo CH, Gosert R, Bernhoff E, et al. 1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother. 2010;54(11):4714–4722.
171. Randhawa P, Zemlicka J, Sauerbrei A, et al. Anti-BK virus activity of nucleoside analogs. Antimicrob Agents Chemother. 2008;52(4):1519–1521.
172. Randhawa P, Farasati NA, Shapiro R, et al. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother. 2006;50(4):1564–1566.
173. Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates:activity against adenovirus replication in vitro. J Infect Dis. 2005;191(3):396–399.
174. Quenelle DC, Collins DJ, Herrod BP, et al. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob Agents Chemother. 2007;51(11):3940–3947.
175. Rice AD, Adams MM, Lampert B, et al. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses. 2011;3(2):63–82.
176. Florescu DF, Pergam SA, Neely MN, et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant. 2012;18(5):731–738.
177. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother. 2002;46(8):2381–2386.
178. Kern ER, Collins DJ, Wan WB, et al. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother. 2004;48(9):3516–3522.
179. Bidanset DJ, Beadle JR, Wan WB, et al. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis. 2004;190(3):499–503.
180. Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227–1236.•• Landmark study on use of CMX001 amog allogeneic HSCT recipients.
181. Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–613.
182. Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85(20):10884–10893.
183. Goldner T, Zimmermann H, Lischka P. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir. Antiviral Res. 2015;116:48–50.
184. Kropeit D., 2010. Phase I safety and PK data of the novel anti-HCMV terminase inhibitor AIC246. Abstract 1994 presented at the 50th Interscience Conference of Antimicrobial Agents and Chemotherapy; Boston, MA.
185. Marschall M, Stamminger T, Urban A, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012;56(2):1135–1137.
186. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;370(19):1781–1789.•• Provides information regarding the new drug Letermovir among HSCT recipients.
187. Stoelben S, Arns W, Renders L, et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir:results of a Phase 2a study. Transpl Int. 2014;27(1):77–86.
188. Kaul DR, Stoelben S, Cober E, et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant. 2011;11(5):1079–1084.
189. Melendez DP, Razonable RR. Letermovir and inhibitors of the terminase complex:a promising new class of investigational antiviral drugs against human cytomegalovirus. Infect Drug Resist. 2015;8:269–277.• Excellent review on the new drug Letermovir.
190. Kern ER, Kushner NL, Hartline CB, et al. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother. 2005;49(3):1039–1045.
191. Kern ER, Bidanset DJ, Hartline CB, et al. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother. 2004;48(12):4745–4753.
192. Abele G, Karlstrom A, Harmenberg J, et al. Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture. Antimicrob Agents Chemother. 1987;31(1):76–80.
193. Ng TI, Shi Y, Huffaker HJ, et al. Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine. Antimicrob Agents Chemother. 2001;45(6):1629–1636.
194. Tyring SK, Plunkett S, Scribner AR, et al. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults:a randomized, double-blind, active-controlled trial. J Med Virol. 2012;84(8):1224–1232.
195. McGuigan C, Pathirana RN, Migliore M, et al. Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus. J Antimicrob Chemother. 2007;60(6):1316–1330.
196. Balzarini J, Sienaert R, Liekens S, et al. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Mol Pharmacol. 2002;61(5):1140–1145.
197. Pentikis HS, Matson M, Atiee G, et al. Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers. Antimicrob Agents Chemother. 2011;55(6):2847–2854.
198. Tyring S, Wald A, Zadeikis N, et al. ASP2151 for the treatment of genital herpes:a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis. 2012;205(7):1100–1110.
199. Wald A, Corey L, Timmler B, et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014;370(3):201–210.• Provides a good discussion on the drug pritelvir, with a novel mechanism of action.
200. Manuel O, Husain S, Kumar D, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients:a multicenter cohort study. Clin Infect Dis. 2013;56(6):817–824.
201. Melendez D, Razonable RR. Immune-based monitoring for cytomegalovirus infection in solid organ transplantation:is it ready for clinical primetime? Expert Rev Clin Immunol. 2014;10(9):1213–1227.•• Provides a good review of the use of immune-based approach to predict CMV infection.
202. Razonable RR. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients. Infect Dis Clin North Am. 2013;27(2):317–342.